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The objective of this study was to determine the pharmacodynamics effects of the anaesthetic alfaxalone in 2-hydroxypropyl-𝛽-
cyclodextrin in pregnant sheep after the intravenous injection of a 2mg/kg weight dose. Six pregnant Ripollesa sheep, weighing 47.1
± 4.4 kg, were used. Twenty-four hours after instrumentation, sheepwere anaesthetizedwith intravenous alfaxalone in cyclodextrin.
Time to standing from anaesthesia was 30.0 ± 10.81min. Foetal heart rate increased significantly during the first 5min after
alfaxalone administration. Significant differences were observed inmaternal diastolic arterial blood pressure betweenminute 10 and
minutes 90, 120, 150, 180, 210, and 240. Significant differences were observed for foetal systolic arterial blood pressure between 5 and
30min after alfaxalone administration. Significant differences in foetal pH were detected during the entire study period, whereas
maternal pH returned to baseline values by 60min after alfaxalone administration. The present study indicated that alfaxalone in
2-hydroxypropyl-𝛽-cyclodextrin administered as an intravenous bolus at 2mg/kg body weight produced minimal adverse effects
and an uneventful recovery from anaesthesia in pregnant sheep and their foetus.
1. Introduction
General anaesthesia is often indicated for surgery during
pregnancy or for caesarean section. Nevertheless, drugs given
to the mother during pregnancy or for caesarean section can
affect the ability of the neonate to survive in and adapt to its
new environment. Neonatal drug elimination is usually slow,
andmany drugs have prolonged effects in the neonatal period
[1]. Use of a short-acting hypnotic providing rapid loss of
consciousness with minimal cardiovascular and respiratory
suppression for both mother and foetus and rapid recovery is
necessary for these patients.
Pregnant ewes have been popularly used as animal mod-
els for placental transfer research as well as for the deter-
mination of the anaesthetic effects in the foetus. Although
extrapolation of results from animals to humans should
be done with caution because of anatomical and physio-
logical differences, sheep have been shown to be the most
appropriate experimental model for studies of placental
transfer of drugs, especially the soluble ones, such as gen-
eral anaesthetics [2, 3]. It has been shown that halothane,
isoflurane, and sevofluranemay produce hypotension both in
the mother and the foetus [4–8]. They can also decrease the
foetal (halothane, isoflurane, and sevoflurane) and maternal
(isoflurane) heart rate and cause an increase in PaCO
2
in
the mother and the foetus, inducing a foetal acidosis [4, 8].
Injectable anaesthetics have also been evaluated. Propofol,
in addition to causing hypotension in the mother, causes an
increase in heart rate of the foetus and an impaired acid-base
balance, in both mother and foetus, with significant foetal
acidosis [9]. Recent studies on etomidate have shown that,
although it causes slight alterations in acid-base equilibrium
of foetuses, it has very little effect on blood pressure and
heart rate making it a good candidate for use in pregnant
patients. Nevertheless, etomidate administration has been
associated with significant adrenal suppression, limiting its
use in pregnant patients [10, 11].
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Alfaxalone (3-alpha-hydroxy-5-alpha-pregnane-11,20-di-
one) in 2-hydroxypropyl-𝛽-cyclodextrin (HPCD) (Alfaxan,
Jurox Pty. Ltd.) is the new formulation of this neurosteroid
anaesthetic characterized by not producing histamine release.
In veterinary medicine, it is used to induce and maintain
general anaesthesia [12–15]. Following intravenous injection,
it has a rapid onset of action, rapid redistribution, and a short
terminal half-life [16]. Experimental studies investigating the
cardiorespiratory and anaesthetic effects of alfaxalone in dogs
[12, 17, 18], cats [14, 19, 20], rabbits [21], and sheep [22]
have shown minimal cardiorespiratory depression, making
alfaxalone an acceptable induction agent. Moreover, alfax-
alone administration has not been associated with adrenal
suppression [23], so it could be useful in pregnant patients.
Nevertheless, to our knowledge, no published studies have
been conducted on the effects of this drug formulation during
gestation.
The aim of the present study was to determine the
cardiovascular effects and the changes in acid-base balance
both for ewes that were 4 months pregnant and their foetuses
after the administration of a single IV bolus of alfaxalone.
2. Material and Methods
All procedures were approved by the Ethical Commission of
Animal andHumanExperimentation (SpanishGovernment)
under the auspices of the Ethical Commission of the Univer-
sitat Auto`nomadeBarcelona (Authorization nos.DARP4544
and CEEAH 791).
Six pregnant Ripollesa breed sheepweighing (mean± SD)
47.1±4.4 kg were included in the study. Mean gestational age
was 120 ± 3.8 days (term 147–150 days).
2.1. Animal Preparation. The anaesthetic and surgical tech-
niques used in our study were similar to those described
by Andaluz et al. [9] with some minor modifications.
Sheep were premedicated with 0.02mg/kg buprenorphine
IM (Buprex, Schering-Plough Laboratories) and 0.2mg/kg
meloxicam IM (Metacam, Boehringer Ingelheim). A single
dose of 4mg/kg propofol (Propofol-Lipuro 1%, Braun) was
administered for anaesthesia induction through an 18-gauge
polyurethane catheter (Vasocan, Braun) placed in the right
cephalic vein. The trachea was intubated with a 9–10mm
endotracheal tube, and anaesthesia was maintained with 2–
2.5% isoflurane (IsoVet, B. Braun) in 100% oxygen through
a circle breathing system. Ventilation was controlled using an
intermittent positive pressure ventilator (SAV2500, B. Braun)
in order to maintain normocapnia during the entire anaes-
thetic period. An orogastric tube was placed and maintained
while the ewe was anaesthetized to prevent regurgitation
and aspiration pneumonia. All animals received an infusion
of lactated Ringer’s solution at a rate of 10mL/kg/h during
the perioperative period and IV antibiotic therapy with
20mg/kg cephazolin (Kurgan, Normon Laboratories) was
administered via the cephalic vein.
Each sheep was positioned in dorsal recumbency. The
neck and the abdomen were prepared aseptically. Firstly,
a small incision was made in the skin over the neck.
The carotid artery was dissected for a 32 cm, 14G plain
polyurethane catheter (Cavafix Certo, B. Braun) placement.
The maternal carotid artery catheter was used for blood
gases determination and for heart rate and blood pressure
measurement. Then, a midline laparotomy was performed,
and through a small hysterotomy, the foetus was delivered
partially to permit adequate exposure for insertion of a
71 cm, 14G plain polyurethane catheter (Drucafix-Splittocan,
B. Braun) into the carotid artery. This catheter was used for
blood gas determination and for heart rate and foetal blood
pressure measurement. The skin of the foetus was incised
over the carotid artery. Fine dissection of the vessels and
placement of the catheter were performed and the catheter
was immediately heparinised and the blood pressure was
measured to ensure the functionality of the catheter. The
skin incision was sutured and the foetus returned to the
uterus. Care was taken during surgery to minimize loss of
amniotic fluid. The placenta and the uterus were closed as
previously described [9]. The foetal catheter was tunnelled
subcutaneously through the ewe’s flank, exteriorized, and
stored in a plastic pouch sewn on the skin of the flank. The
laparotomy incision was closed in a routine manner.
Throughout the surgical process, temperature, cardiac
frequency, respiratory frequency, capnography, arterial pres-
sure, pulse, and electrocardiography were monitored using a
multifunction patient VetCare monitor (B. Braun).
Following recovery from anaesthesia, sheep were
returned to their pen and allowed to recover for 24 h before
the experimental phase began. During this period, ewe and
foetal arterial catheters were heparinised every 8 h to avoid
occlusion. Animals were treated with SC buprenorphine
(0.02mg/kg every 6 h) and meloxicam (0.1mg/kg every 24
hours) for pain control after surgery.
2.2. Experimental Design. During the study period, mater-
nal and foetal heart rate, arterial blood pressure (systolic,
diastolic, and mean), and maternal respiratory rate were
determined at different times using a multifunction patient
VetCare monitor (B. Braun). Foetal and maternal arterial
blood samples were also taken at different times for acid-
base variables evaluation using an i-STAT Portable Clinical
Analyzer. Blood samples for acid-base determination were
collected into a 1mL heparinised insulin syringe and pro-
cessed within 5min.
All efforts were made to keep the sheep in sternal
recumbency during the anaesthetic periods. The appearance
of adverse effects (salivation, regurgitation, myoclonus, and
apnoea) was recorded if present. Time to recovery from
anaesthesia (standing) was also recorded.
Before starting the study, a control period of 60min was
established. Baseline values for heart rate, blood pressure,
respiratory rate, and EtCO
2
represent the means of four
determinations taken at 15min intervals, while baseline
values for blood gases were measured only once at minute 30.
After the 60min control period, a single IV bolus of
2mg/kg alfaxalone was administered through the cephalic
vein catheter and both maternal and foetal cardiovascular
variables were measured at 2, 5, 10, 15, 20, 30, 45, 60, 90,
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Table 1: Changes in maternal cardiovascular variables following administration of a single intravenous bolus of 2mg/kg of alfaxalone in a
2-hydroxypropyl-𝛽-cyclodextrin formulation (mean ± SD).
HR (bpm) SAP (mmHg) DAP (mmHg) MAP (mmHg) RR (rpm)
Baseline values 126.00 ± 20.56 96.00 ± 19.06 63.16 ± 14.71 760.50 ± 16.18 48.83 ± 15.98
2min 130.60 ± 16.86 81.16 ± 16.00 57.16 ± 40.60 67.00 ± 39.02 30.00 ± 8.29
5min 133.40 ± 18.80 90.00 ± 19.66 65.5 ± 19.59 73.16 ± 16.43 29.33 ± 13.54
10min 134.20 ± 23.49 103.3 ± 25.15 80.83 ± 14.16 88.67 ± 19.02 37.00 ± 14.41
15min 134.50 ± 28.72 102.7 ± 14.45 79.00 ± 14.41 86.83 ± 13.01 39.67 ± 14.56
20min 140.20 ± 24.63 101.50 ± 10.23 78.67 ± 11.47 87.5 ± 10.03 39.67 ± 8.98
30min 150.30 ± 24.48 93.5 ± 17.63 64.00 ± 10.90 73.83 ± 9.84 42.67 ± 11.22
45min 133.20 ± 12.92 96.33 ± 18.18 64.17 ± 20.72 78.00 ± 19.24 47.33 ± 9.26
60min 130.80 ± 18.73 91.8 ± 13.54 64.00 ± 7.24 74.00 ± 10.61 57.00 ± 25.73
90min 115.00 ± 13.37 89.8 ± 19.76 53.80 ± 15.15∗ 63.00 ± 13.32 62.40 ± 26.32
120min 117.75 ± 25.95 81.6 ± 8.23 50.60 ± 17.99∗ 63.8 ± 14.41 71.20 ± 36.15
150min 125.20 ± 12.02 93.25 ± 17.85 56.00 ± 25.17∗ 71.75 ± 20.18 60.80 ± 41.12
180min 120.80 ± 12.81 80.2 ± 10.47 59.8 ± 15.31∗ 68.4 ± 12.58 57.60 ± 36.50
210min 121.60 ± 15.37 91.6 ± 12.22 61.20 ± 22.55∗ 74.80 ± 17.22 48.00 ± 14.42
240min 109.50 ± 12.71 90.80 ± 24.78 62.00 ± 32.83∗ 76.00 ± 27.91 50.80 ± 20.95
∗Significant differences from min 10.
HR: heart rate; SAP: systolic arterial pressure; DAP: diastolic arterial pressure; MAP: mean arterial pressure; RR: respiratory rate.
120, 150, 180, 210, and 240min after alfaxalone injection.
Blood samples for acid-base status evaluation were taken
simultaneously from mother and foetus at 5, 15, 30, 60, 120,
and 240min after alfaxalone injection.
All animals were monitored and received a lactated
Ringer’s solution therapy at 60mL/kg/day for the entire study
period. If episodes of apnoea occurred, artificial ventilation
was initiated until spontaneous respiration was regained.
Data were analyzed using a statistical computer software
program (SPSS v19.0, SPSS Ibe´rica). Normality was tested
using the Shapiro-Wilk statistic. The results were analyzed
by analysis of variance using a mixed model, including
time as fixed effect and sheep as the random effect. When
significant differences were found, a Bonferroni post hoc
analysis for pairwise comparisons was performed. A value of
𝑃 < 0.05was considered to be significant. To evaluate time of
anaesthesia and time to standing, one-sample t-test was used.
3. Results
Time to standing from anaesthesia, after a single IV bolus
of 2mg/kg body weight of alfaxalone in ewes, was 30.0 ±
10.81min (mean ± SD). No adverse effects were observed
after alfaxalone injection.
3.1. Maternal Variables. Maternal cardiovascular and acid-
base variables are shown in Tables 1 and 2.
No significant differences were observed in maternal
heart rate (HR) and systolic (SAP) and mean (MAP) arterial
blood pressure during the entire study period. Significant
differences were observed in diastolic arterial blood pressure
(DAP) between minute 10 and the minutes 90, 120, 150, 180,
210, and 240.
A significant decrease from baseline values was observed
in maternal pH 5 minutes after alfaxalone administration
(𝑃 < 0.05); this returned to baseline at 30min.This alteration
was accompanied by a significant increase in PaCO
2
5min
after alfaxalone administration from the baseline value and a
significant decrease in PaO
2
during min 5 and 15 compared
with the entire study period (𝑃 < 0.05).
3.2. Foetal Variables. Foetal cardiovascular and acid-base
variables are shown in Tables 3 and 4.
Foetal heart rate was significantly increased during min-
utes 2 and 5 after alfaxalone administration (𝑃 < 0.05). Foetal
arterial blood pressure remained constant during the entire
study period compared to the control period.Only significant
differences in SAP between minutes 5 and 30 were observed.
Foetal pH decreased and PaCO
2
increased following a
similar pattern as that described for maternal pH although
significant differences (𝑃 < 0.05) from the baseline value
remained during the entire study period only for pH. No






To the authors’ knowledge, this is the first published study in
which alfaxalone in HPCD has been evaluated in pregnant
ewes.
The alfaxalone dosages used and the times chosen for
recording all the variables were those described previously for
alfaxalone in nonpregnant sheep by Andaluz et al. [22].
Time to standing was longer in the present study (30.0 ±
10.81min) than that described in nonpregnant sheep (22.0 ±
10.6min) [22]. As pregnancy-associated alterations in phys-
iological function affect the uptake, distribution, and dispo-
sition of anaesthetic agents [24], the results observed in the
present study may indicate that elimination of alfaxalone in
pregnant sheep could be slower than in nonpregnant ones.
Several investigations have postulated that the dose of drugs
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Table 2: Changes in maternal acid-base variables following administration of a single intravenous bolus of 2mg/kg of alfaxalone in a 2-
hydroxypropyl-𝛽-cyclodextrin formulation (mean ± SD).
pH PaCO2 (mmHg) PaO2 (mmHg) HCO3
− (mmol/L) Base excess (mmol/L)
Baseline values 7.57 ± 0.04 27.33 ± 2.92 89.67 ± 15.15†,‡ 24.82 ± 2.26 2.67 ± 2.34
5min 7.50 ± 0.06∗ 33.72 ± 1.59∗ 68.50 ± 16.16 25.52 ± 2.94 2.17 ± 3.76
15min 7.49 ± 0.04∗ 32.33 ± 2.94 70.67 ± 16.44 25.45 ± 2.83 3.00 ± 3.95
30min 7.54 ± 0.05 29.32 ± 3.09 83.83 ± 18.05†,‡ 25.00 ± 4.50 2.50 ± 5.24
60min 7.52 ± 0.06 28.82 ± 0.91 90.20 ± 4.97†,‡ 23.50 ± 2.62 0.80 ± 3.63
120min 7.53 ± 0.05 29.56 ± 3.28 99.40 ± 10.74†,‡ 24.68 ± 3.88 2.00 ± 4.47
240min 7.51 ± 0.06 29.72 ± 1.98 103.00 ± 11.25†,‡ 24.06 ± 4.03 1.00 ± 5.15
∗Significant differences from baseline values.
†Significant differences from min 5.
‡Significant differences from min 15.
Table 3: Changes in foetal cardiovascular variables following maternal administration of a single intravenous bolus of 2mg/kg of alfaxalone
in a 2-hydroxypropyl-𝛽-cyclodextrin formulation (mean ± SD).
HR (bpm) SAP (mmHg) DAP (mmHg) MAP (mmHg)
Baseline values 197.16 ± 34.80 59.66 ± 8.09 36.66 ± 3.72 46.16 ± 4.62
2min 251.00 ± 77.31∗ 66.83 ± 8.63 48.16 ± 9.80 54.16 ± 7.02
5min 271.50 ± 33.94∗ 73.33 ± 18.26 47.00 ± 9.12 57.16 ± 8.32
10min 217.00 ± 39.35 59.00 ± 8.60 44.17 ± 7.96 50.5 ± 7.42
15min 222.2 ± 34.58 59.67 ± 10.52 38.17 ± 8.20 47.83 ± 6.52
20min 208.50 ± 32.26 56.67 ± 12.53 40.33 ± 5.57 46.00 ± 7.61
30min 208.20 ± 32.25 53.00 ± 7.07† 38.50 ± 5.50 46.50 ± 4.03
45min 198.70 ± 27.69 61.33 ± 14.05 40.33 ± 7.60 49.00 ± 8.92
60min 187.50 ± 28.70 56.83 ± 10.09 40.83 ± 5.26 48.00 ± 6.87
90min 193.33 ± 22.23 59.83 ± 9.74 43.5 ± 6.47 50.16 ± 5.49
120min 226.83 ± 45.77 65.83 ± 17.26 45.66 ± 13.30 56.00 ± 14.68
150min 189.17 ± 28.80 59.66 ± 5.81 45.66 ± 7.84 52.66 ± 5.42
180min 191.5 ± 27.60 64.66 ± 7.44 47.83 ± 7.75 54.83 ± 7.41
210min 209.00 ± 34.89 69.66 ± 15.05 48.00 ± 9.57 56.16 ± 13.89
240min 187.50 ± 22.74 62.33 ± 7.00 46.33 ± 10.09 53.16 ± 5.84
∗Significant differences from baseline values.
†Significant differences from min 5.
HR: heart rate; SAP: systolic arterial pressure; DAP: diastolic arterial pressure; MAP: mean arterial pressure; RR: respiratory rate.
Table 4: Changes in foetal acid-base variables following maternal administration of a single intravenous bolus of 2mg/kg of alfaxalone in a
2-hydroxypropyl-𝛽-cyclodextrin formulation (mean ± SD).
pH PaCO2 (mmHg) PaO2 (mmHg) HCO3
− (mmol/L) Base excess (mmol/L)
Baseline values 7.47 ± 0.02 37.30 ± 2.45 20.00 ± 9.34 27.17 ± 2.32 3.50 ± 2.35
5min 7.39 ± 0.05∗ 43.12 ± 4.26 16.33 ± 7.81 26.25 ± 2.81 1.00 ± 2.76
15min 7.43 ± 0.04∗ 41.00 ± 4.57 21.17 ± 7.70 26.85 ± 4.18 2.33 ± 4.41
30min 7.42 ± 0.03∗ 39.65 ± 4.34 20.00 ± 7.72 25.70 ± 3.21 1.17 ± 3.54
60min 7.44 ± 0.03∗ 38.83 ± 3.03 19.33 ± 9.27 26.53 ± 2.36 2.33 ± 2.73
120min 7.41 ± 0.04∗ 40.39 ± 1.74 17.49 ± 8.61 25.62 ± 2.36 0.96 ± 3.06
240min 7.39 ± 0.05∗ 41.51 ± 1.78 19.20 ± 8.25 25.86 ± 3.10 1.35 ± 2.98
∗Significant differences from baseline values.
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in pregnant patients should be decreased by 25% compared to
the usual dose [24]. This reduction has not been performed
in this study, so that this could have prolonged the recovery
time from anaesthesia.
As described for nonpregnant sheep, apnoea or other
adverse effects did not occur in any of the animals of this
study.However, apnoea is one of themost frequently reported
side effects after alfaxalone use.The slow administration rate,
as postulated by Andaluz et al. [22] in nonpregnant ewes,
or the possibility that sheep are less sensitive to the apnoea
produced by this drug could explain these results. Although
apnoea was not observed in any of the sheep, it seems that
alfaxalone tends to produce a respiratory depression that is
manifested by the transient decrease in pH and the increase
in PaCO
2
. However, pH remained within the clinically
acceptable range for sheep (7.48–7.58) [25] throughout the
study, so it is not expected that those alterations would have
an important clinical implication.This respiratory depression
is also seen in foetuses, in which the pH is decreased
significantly during the entire study period. These results
agree with those reported for alfaxalone in nonpregnant
sheep [22] and are very similar to those described by Fresno et
al. [11] for etomidate administration in ewes. This may show
that both, alfaxalone and etomidate, present a good stability
on the respiratory system, which makes them optimal for
anaesthesia induction in pregnant patients. The results also
resemble those described for sevoflurane and isoflurane in
pregnant ewes [8], especially when they are administered at
1.5 to 2 minimal alveolar concentration (MAC).
Moreover, as observed in nonpregnant sheep [22], alfax-
alone did not produce significant cardiovascular depression
in the ewe.The increase in heart rate observed in nonpregnant
sheep, attributed to the lateral recumbent position of the
animals during the study, has not been observed in pregnant
sheep. The cardiovascular adverse effects observed in the
previous study may have been avoided by the maintenance
of sheep in sternal recumbency in the present study. These
results show that the cardiovascular safety of alfaxalone in
pregnant sheep is similar to that described for etomidate [11],
isoflurane, and sevoflurane [8] and higher than that described
for propofol, as the latter produces a marked hypotension
immediately after its administration in pregnant ewes [9].
However, cardiovascular stability of etomidate appears to
be superior to that of alfaxalone in the foetus. Intravenous
bolus of alfaxalone, as observed previously with propofol
[9], produces a significant increase in heart rate. This effect
has been associated with foetal response to maternal stress
during anaesthesia induction and with foetal distress caused
by a reduction in the uterine blood flow [26]. The decrease
in foetal PaO
2
may also have contributed to the increase
in heart rate. Oxygen supplementation prior to alfaxalone
administration as well as during early recovery may have
diminished this effect. For this reason, although sheep used
in the present study did not receive oxygen supplementation,
the authors strongly recommend to oxygenate patients before
and during induction of anaesthesia.
Although inhalant anaesthetic agents may be used for
anaesthesia induction, this technique is not the most recom-
mended in many patients as it can be slow, delaying the time
of endotracheal intubation and increasing the probability of
vomiting and aspiration pneumonia. Moreover, induction
with inhalant anaesthetic agents may cause agitation when
no sedative agents have been used, which often happens
with pregnant patients. Because etomidate may result in the
suppression of foetal serum cortisol concentrations [27] and
propofol in severe hypotension, especially in patients with
haemodynamic instability, alfaxalone in HPCD may be a
useful option for anaesthesia induction in pregnant animal
patients if care is taken to ensure optimal oxygenation and
ventilatory support.
It can be concluded that the administration of a sin-
gle bolus of alfaxalone in HPCD has no apparent major
adverse effects on the pregnant ewe when compared to those
described in nonpregnant animals or those described in
pregnant ewes undergoing inhalant or propofol anaesthesia.
However, as respiratory effects on the foetuses could be
important, the authors recommend to provide 100% oxygen
to ewes in order to prevent hypoxia and foetal respiratory
acidosis during alfaxalone anaesthesia.
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